PubRank

Maria Pia Amato

Author PubWeight™ 47.51‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007 3.87
2 International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013 2.20
3 Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 2009 1.88
4 Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology 2013 1.61
5 Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurol 2012 1.18
6 Coping strategies, psychological variables and their relationship with quality of life in multiple sclerosis. Neurol Sci 2009 1.14
7 Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One 2012 1.12
8 Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. PLoS One 2011 1.05
9 Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLoS One 2012 1.04
10 Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry 2007 1.02
11 Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs 2009 1.02
12 Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Mult Scler 2009 0.99
13 Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. J Neuroimmunol 2008 0.97
14 Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. PLoS One 2010 0.97
15 Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. Mult Scler 2012 0.97
16 The management of multiple sclerosis in children: a European view. Mult Scler 2010 0.95
17 Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol 2012 0.94
18 Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Ann Neurol 2014 0.91
19 Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord 2010 0.91
20 Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One 2013 0.89
21 International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology 2013 0.89
22 Relevance of brain lesion location to cognition in relapsing multiple sclerosis. PLoS One 2012 0.88
23 Neocortical volume decrease in relapsing-remitting multiple sclerosis with mild cognitive impairment. J Neurol Sci 2006 0.87
24 Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurol Sci 2013 0.87
25 Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One 2013 0.86
26 Relevance of hypointense brain MRI lesions for long-term worsening of clinical disability in relapsing multiple sclerosis. Mult Scler 2013 0.86
27 Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain 2006 0.86
28 Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurol 2011 0.85
29 Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci 2009 0.84
30 Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol 2012 0.84
31 Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. J Neurol Sci 2006 0.83
32 Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 2013 0.83
33 Changes in neuropsychological test performance over the workday in multiple sclerosis. Clin Neuropsychol 2003 0.83
34 Natalizumab: a country-based surveillance program. Neurol Sci 2008 0.82
35 Cortical functional reorganization and its relationship with brain structural damage in patients with benign multiple sclerosis. Mult Scler 2010 0.82
36 Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. J Neurol Sci 2007 0.82
37 The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. BMC Neurol 2014 0.81
38 Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 2013 0.80
39 Impact of cognitive impairment on coping strategies in multiple sclerosis. Clin Neurol Neurosurg 2009 0.80
40 Clinical correlations of CSF single IgG bands. J Neurol 2005 0.80
41 Increased CD8+ T cell responses to apoptotic T cell-associated antigens in multiple sclerosis. J Neuroinflammation 2013 0.79
42 Posterior brain damage and cognitive impairment in pediatric multiple sclerosis. Neurology 2014 0.79
43 Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch Neurol 2004 0.79
44 APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. Mult Scler 2009 0.79
45 Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II). Qual Life Res 2011 0.78
46 Assessing executive function with the D-KEFS sorting test: normative data for a sample of the Italian adult population. Neurol Sci 2014 0.78
47 Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology 2007 0.77
48 Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study. Ther Adv Neurol Disord 2009 0.77
49 Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS. J Neurol Sci 2009 0.75
50 Cognitive rehabilitation in children and adolescents with multiple sclerosis. Neurol Sci 2010 0.75
51 Motor evoked potentials in multiple sclerosis patients without walking limitation: amplitude vs. conduction time abnormalities. J Neurol 2007 0.75
52 Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. Clin Neurol Neurosurg 2012 0.75
53 Cognitive and psychosocial issues in pediatric multiple sclerosis: where we are and where we need to go. Neuropediatrics 2012 0.75